NASDAQ:CTXR

Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

Citius Pharmaceuticals logo
$0.52 -0.01 (-1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$0.52 0.00 (-0.15%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Citius Pharmaceuticals Stock (NASDAQ:CTXR)

Advanced

Key Stats

Today's Range
$0.50
▼
$0.54
50-Day Range
$0.37
▼
$0.60
52-Week Range
$0.37
▼
$1.54
Volume
117,023 shs
Average Volume
292,918 shs
Market Capitalization
$14.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Citius Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for serious medical conditions. Its work has included products and drug candidates in oncology and critical care, with an emphasis on addressing unmet treatment needs.

Its oncology business is associated with LYMPHIR (denileukin diftitox-cxdl), an FDA-approved treatment for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. Citius has also developed Mino-Lok, an investigational antibiotic lock solution intended to treat catheter-related bloodstream infections.

The company’s activities have included advancing its own drug candidates as well as building an oncology business around LYMPHIR. Citius Pharmaceuticals is based in the United States.

AI Generated. May Contain Errors.

Citius Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

CTXR MarketRank™: 
1.921746073995 of 5 stars

Citius Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 673rd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Citius Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Citius Pharmaceuticals has a consensus price target of $6.00, representing about 1,056.5% upside from its current price of $0.52.

  • Amount of Analyst Coverage

    Citius Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Citius Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.44) per share.

  • Price to Book Value per Share Ratio

    Citius Pharmaceuticals has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Citius Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    22.10% of the float of Citius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Pharmaceuticals has a short interest ratio ("days to cover") of 17.76, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Citius Pharmaceuticals has recently increased by 1.17%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Citius Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Citius Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Citius Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Citius Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.99% of the stock of Citius Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    16.88% of the stock of Citius Pharmaceuticals is held by institutions.

  • Read more about Citius Pharmaceuticals' insider trading history.
Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTXR Stock News Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Headlines

CTXR Stock Analysis - Frequently Asked Questions

Citius Pharmaceuticals' stock was trading at $0.7770 at the beginning of the year. Since then, CTXR stock has decreased by 33.2% and is now trading at $0.5188.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) released its quarterly earnings results on Friday, August, 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02.

Shares of Citius Pharmaceuticals reverse split on Tuesday, November 26th 2024.The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), Palantir Technologies (PLTR) and Energy Transfer (ET).

Company Calendar

Last Earnings
8/14/2026
Today
11/17/2026
Next Earnings (Estimated)
12/22/2026
Fiscal Year End
9/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CTXR
CIK
1506251
Fax
N/A
Employees
23
Year Founded
2007

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Potential Upside/Downside
+1,056.5%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.43 million
Net Margins
N/A
Pretax Margin
-816.00%
Return on Equity
-59.57%
Return on Assets
-34.47%

Debt

Debt-to-Equity Ratio
0.08
Current Ratio
0.84
Quick Ratio
0.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.29 per share
Price / Book
0.12

Miscellaneous

Outstanding Shares
27,450,000
Free Float
26,083,000
Market Cap
$14.24 million
Optionable
Optionable
Beta
1.05

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:CTXR) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners